{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '10.0 REFERENCES', '1. Vahlquist A, Ganemo A, Virtanen M. Congenital ichthyosis: an overview of current and', 'emerging therapies. Acta Derm Venereol. 2008;88:4-14.', '2. Takeichi T, Akiyama M. Inherited ichthyosis: Non-syndromic forms. J Dermatol.', '2016;43:242-51.', '3. Nomura K, Nakano H, Umeki K, et al. A study of the steroid sulfatase gene in families with', 'X-linked ichthyosis using polymerase chain reaction. Acta Derm Venereol. 1995;75:340-2.', '4.', 'Vahlquist A, Blockhuys S, Steijlen P, et al. Oral liarozole in the treatment of patients with', 'moderate/severe lamellar ichthyosis: Results of a randomized, double-blind, multinational,', 'placebo-controlled phase II/III trial. Br J Dermatol. 2014;170:173-81.', '5. Digiovanna JJ, Mauro T, Milstone LM, Schmuth M, Toro JR. Systemic retinoids in the', 'management of ichthyoses and related skin types. Dermatol Ther. 2013;26:26-38.', '6.', 'Isotrex R (isotretinoin) Gel, 0.05% (Australian Register of Therapeutic Goods Product', 'Information). Abbotsford Victoria, Australia: GlaxoSmithKline Australia Pty Ltd; 2013.', '7. Layton A. The use of isotretinoin in acne. Dermatoendocrinol 2009;1:162-9.', '8. Blaner WS. Cellular metabolism and actions of 13-cis-retinoic acid. J Am Acad Dermatol.', '2001;45:S129-S135.', '9. AccutaneR (isotretinoin) capsules, 10-mg, 20-mg, 40-mg (US Package Insert). Nutley, NJ:', 'Roche Laboratories Inc; 1982.', '10. Isotrex R (isotretinoin) Cream, 0.05% (UK Package Leaflet). Uxbridge, Middlesex, UK:', 'GlaxoSmithKline UK Limited; 2014.', \"11. Burge SM, Buxton PK. Topical isotretinoin in Darier's disease. Br J Dermatol.\", '1995;133:924-8.', '12. Steijlen PM, Reifenschweiler DO, Ramaekers FC, et al. Topical treatment of ichthyoses and', \"Darier's disease with 13-cis-retinoic acid. A clinical and immunohistochemical study. Arch\", 'Dermatol Res. 1993;285:221-6.', '13. Chalker DK, Lesher JL Jr., Smith JG, Jr., et al. Efficacy of topical isotretinoin 0.05% gel in', 'acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol.', '1987;17:251-4.', '14. Dominguez J, Hojyo MT, Celayo JL, Dominguez-Soto L, Teixeira F. Topical isotretinoin VS.', 'topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol. 1998;37:54-5.', '51']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '15. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%,', 'benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol.', '1992;17:165-8.', '16. loannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel', '0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J', 'Dermatol. 2002;147:523-7.', '17. Jensen BK, McGann LA, Kachevsky V, Franz TJ. The negligible systemic availability of', 'retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in', 'patients with acne vulgaris. J Am Acad Dermatol. 1991;24:425-8.', '18. 3136456. Risk evaluation and mitigation strategy (REMS): The iPLEDGE Program - single', 'shared system for isotretinoin. Apr 2012. Accessed 15 Aug 2019.', 'https://www.fda.gov/media/80023/download,', '52']\n\n###\n\n", "completion": "END"}